Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial-Reference-Cited by-同舟云学术

Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial

Published:2019 Issue:6 Volume:24 Page:425-435
ISSN:1359-6535
Container-title:Antiviral Therapy
language:
Short-container-title:Antivir Ther

Author:

Gatell Jose M,Morales-Ramirez Javier O,Hagins Debbie P,Thompson Melanie,Arastéh Keikawus,Hoffmann Christian,Raffi François,Osiyemi Olayemi,Dretler Robin,Harvey Charlotte,Xu Xia,Plettenberg Andreas,Smith Don E,Portilla Joaquín,Rugina Sorin,Kumar Sushma,Frobose Colleen,Wan Hong,Rodgers Anthony,Hwang Carey,Teppler Hedy

Publisher

SAGE Publications

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV;AIDS;2024-07-02

2. In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine;Therapeutic Drug Monitoring;2023-12-26

3. Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014;Journal of the Pediatric Infectious Diseases Society;2023-10-10

4. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting;Viruses;2023-07-23

5. Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model;International Journal of Molecular Sciences;2023-07-19